Literature DB >> 10899284

Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes.

R D Azbill1, X Mu, J E Springer.   

Abstract

The purpose of this study was to examine the effect of the anti-convulsant agent, riluzole, on high-affinity glutamate uptake as measured in rat spinal cord synaptosomes. The rate of glutamate uptake was significantly increased in the presence of 0.1 microM and 1.0 microM riluzole, but not at the higher concentrations examined. Kinetics analysis demonstrated that riluzole (0.1 microM) decreased the apparent K(m) by 21% and increased the V(max) by 31%. Glutamate uptake also was significantly increased in spinal cord synaptosomes obtained from rats treated with 8 mg/kg (i.p.) of riluzole and sacrificed 4 h later. The increase in glutamate uptake in vitro was not affected by pretreatment either with H7, an inhibitor of PKA and PKC, or with the PKC activating phorbol ester, 12-O-tetradecanoylphorbol 13-acetate. Previous studies have shown that some of the actions of riluzole are mediated by G proteins sensitive to pertussis toxin. Surprisingly, treatment of synaptosomes with pertussis toxin alone increased the rate of glutamate uptake, while having no effect on uptake in the presence of riluzole. However, pretreatment with cholera toxin was found to completely block the effects of riluzole on glutamate uptake. These results reveal an additional mechanism by which riluzole can affect glutamatergic neurotransmission, and provides further support that riluzole may prove beneficial in the treatment of traumatic central nervous system injuries involving the excitotoxic actions of glutamate.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10899284     DOI: 10.1016/s0006-8993(00)02430-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  56 in total

Review 1.  Links between electrophysiological and molecular pathology of amyotrophic lateral sclerosis.

Authors:  Katharina A Quinlan
Journal:  Integr Comp Biol       Date:  2011-10-11       Impact factor: 3.326

2.  Glial and glutamatergic markers in depression, alcoholism, and their comorbidity.

Authors:  José Javier Miguel-Hidalgo; Robert Waltzer; Angela A Whittom; Mark C Austin; Grazyna Rajkowska; Craig A Stockmeier
Journal:  J Affect Disord       Date:  2010-06-26       Impact factor: 4.839

3.  Targeting glial physiology and glutamate cycling in the treatment of depression.

Authors:  Gerald W Valentine; Gerard Sanacora
Journal:  Biochem Pharmacol       Date:  2009-04-17       Impact factor: 5.858

Review 4.  A brief history of the development of antidepressant drugs: from monoamines to glutamate.

Authors:  Todd M Hillhouse; Joseph H Porter
Journal:  Exp Clin Psychopharmacol       Date:  2015-02       Impact factor: 3.157

5.  Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models.

Authors:  Holly C Hunsberger; Sharay E Setti; Ryan T Heslin; Jorge E Quintero; Greg A Gerhardt; Miranda N Reed
Journal:  J Vis Exp       Date:  2017-05-03       Impact factor: 1.355

6.  Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity.

Authors:  Jianren Mao; Backil Sung; Ru-Rong Ji; Grewo Lim
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

Review 7.  Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Lobna A Ibrahim; Nancy Diaz-Granados; Carlos A Zarate
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

8.  Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole.

Authors:  M Banasr; G M I Chowdhury; R Terwilliger; S S Newton; R S Duman; K L Behar; G Sanacora
Journal:  Mol Psychiatry       Date:  2008-09-30       Impact factor: 15.992

9.  Past, present and future therapeutics for cerebellar ataxias.

Authors:  D Marmolino; M Manto
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

10.  Gene transfer of GLT-1, a glial glutamate transporter, into the spinal cord by recombinant adenovirus attenuates inflammatory and neuropathic pain in rats.

Authors:  Sanae Maeda; Ai Kawamoto; Yumi Yatani; Hisashi Shirakawa; Takayuki Nakagawa; Shuji Kaneko
Journal:  Mol Pain       Date:  2008-12-24       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.